Search Within

Charisse Palad Capadona

Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Advanced Practice Providers (4)
  2. Center for Hematologic Malignancies (4)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (4)
  4. Department of Medicine (4)
  5. Department of Pathology and Laboratory Medicine (4)
  6. GSK Faculty (4)

More Groups

People
  1. Ahmet Dogan (4)
  2. Alison Moskowitz (4)
  3. Andrew Intlekofer (4)
  4. Andrew Zelenetz (4)
  5. Anita Kumar (4)
  6. Ariela Noy (4)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (1)
Publications
  1. Hematological Oncology (2)
  2. Blood (1)
  3. Journal of Clinical Oncology (1)
Publishers
  1. Wiley Blackwell (2)
  2. American Society of Clinical Oncology (1)
  3. American Society of Hematology (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save